Toxicity profile of main dual-targeting CAR products for B-cell ALL
| Reference . | Grading system used . | n . | CRS . | Neurotoxicity (ICANS) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | Grade 5 . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | Grade 5 . | |||
| Wang et al53 | CTCAE68 | 89 (B-cell ALL + B-NHL) | 66 (74%) | — | 15 (17%) | 3 (3%) | 1 (1%) | 11 (12%) | 0 | 0 | 1 (1%) | 0 |
| Pan et al55 | 20 Cycle 1 20 Cycle 2 | 17 (85%) 15 (75%) | 1 (5%) 0 | 0 | 3 (15%) 3 (15%) | 0 | 1 (5%) 0 | 0 | 0 | |||
| Liu et al56 | 27 first 21 second | 3 (11%) 8 (38%) | 13 (48%) 3 (11%) | 5 (19%) 0 | 1 (4%) 0 | 1 (4%) 0 | 1 (4%) — | 1 (4%) — | 1 (4%) — | — | — | |
| Wang et al50 | 225 | 133 (59%) | 64 (28%) | 1 (0.4%) | 36 (16%) | 9 (4%) | 2 (0.8%) | |||||
| Zhang et al54 | ASTCT69 | 4 | 2 (50%) | 0 | 1 (25%) | 0 | — | 1 (25%) | 0 | 0 | 0 | — |
| Pan et al57 | 81 cycle 1 79 cycle 2 | 60 (74%) 54 (68%) | 12 (15%) 2 (3%) | 1 (1%) 2 (3%) | — | 19 (23%) 13 (16%) | 3 (4%) 1 (1%) | 1 (1%) 0 | — | |||
| Gardner et al58 | 7 | 5 (71%) | — | — | — | — | 2 (29%) | 0 | 0 | 0 | — | |
| Annesley et al59 | 12 | 5 (42%) | — | — | — | — | 4 (33%) | 0 | 1 (8%) | 0 | — | |
| Ghorashian et al60 | 12 | 5 (42%) | 6 (50%) | — | — | — | 4 (33%) | 1 (8%) | 0 | 1 (8%) | — | |
| Cordoba et al49 | 15 | 11 (73%) | 1 (7%) | — | — | — | 4 (27%) | 0 | 0 | 0 | — | |
| Dai et al61 | 6 | 4 (67%) | 2 (33%) | 0 | 0 | — | 0 | 0 | 0 | 0 | — | |
| Spiegel et al62 | 17 | 5 (29%) | 7 (41%) | — | 1 (6%) | — | 1 (6%) | 1 (6%) | 2 (12%) | 1 (6%) | — | |
| Hu et al63 | 6 | 3 (50%) | 2 (33%) | 1 (17%) | 0 | — | 0 | 0 | 0 | 0 | — | |
| Cui et al64 | 47 | 33 (70%) | 8 (17%) | — | 1 (2%) | 0 | 0 | 0 | — | |||
| Niu et al65 | 15 | 2 (13%) | 2 (13%) | 0 | 0 | — | 1 (7%) | 0 | 0 | 0 | — | |
| Shalabi et al66 | 20 | 7 (35%) | — | 3 (15%) | — | — | 0 | 0 | 1 (5%) | 0 | — | |
| Reference . | Grading system used . | n . | CRS . | Neurotoxicity (ICANS) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | Grade 5 . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | Grade 5 . | |||
| Wang et al53 | CTCAE68 | 89 (B-cell ALL + B-NHL) | 66 (74%) | — | 15 (17%) | 3 (3%) | 1 (1%) | 11 (12%) | 0 | 0 | 1 (1%) | 0 |
| Pan et al55 | 20 Cycle 1 20 Cycle 2 | 17 (85%) 15 (75%) | 1 (5%) 0 | 0 | 3 (15%) 3 (15%) | 0 | 1 (5%) 0 | 0 | 0 | |||
| Liu et al56 | 27 first 21 second | 3 (11%) 8 (38%) | 13 (48%) 3 (11%) | 5 (19%) 0 | 1 (4%) 0 | 1 (4%) 0 | 1 (4%) — | 1 (4%) — | 1 (4%) — | — | — | |
| Wang et al50 | 225 | 133 (59%) | 64 (28%) | 1 (0.4%) | 36 (16%) | 9 (4%) | 2 (0.8%) | |||||
| Zhang et al54 | ASTCT69 | 4 | 2 (50%) | 0 | 1 (25%) | 0 | — | 1 (25%) | 0 | 0 | 0 | — |
| Pan et al57 | 81 cycle 1 79 cycle 2 | 60 (74%) 54 (68%) | 12 (15%) 2 (3%) | 1 (1%) 2 (3%) | — | 19 (23%) 13 (16%) | 3 (4%) 1 (1%) | 1 (1%) 0 | — | |||
| Gardner et al58 | 7 | 5 (71%) | — | — | — | — | 2 (29%) | 0 | 0 | 0 | — | |
| Annesley et al59 | 12 | 5 (42%) | — | — | — | — | 4 (33%) | 0 | 1 (8%) | 0 | — | |
| Ghorashian et al60 | 12 | 5 (42%) | 6 (50%) | — | — | — | 4 (33%) | 1 (8%) | 0 | 1 (8%) | — | |
| Cordoba et al49 | 15 | 11 (73%) | 1 (7%) | — | — | — | 4 (27%) | 0 | 0 | 0 | — | |
| Dai et al61 | 6 | 4 (67%) | 2 (33%) | 0 | 0 | — | 0 | 0 | 0 | 0 | — | |
| Spiegel et al62 | 17 | 5 (29%) | 7 (41%) | — | 1 (6%) | — | 1 (6%) | 1 (6%) | 2 (12%) | 1 (6%) | — | |
| Hu et al63 | 6 | 3 (50%) | 2 (33%) | 1 (17%) | 0 | — | 0 | 0 | 0 | 0 | — | |
| Cui et al64 | 47 | 33 (70%) | 8 (17%) | — | 1 (2%) | 0 | 0 | 0 | — | |||
| Niu et al65 | 15 | 2 (13%) | 2 (13%) | 0 | 0 | — | 1 (7%) | 0 | 0 | 0 | — | |
| Shalabi et al66 | 20 | 7 (35%) | — | 3 (15%) | — | — | 0 | 0 | 1 (5%) | 0 | — | |
ASTCT, American Society for Transplantation and Cellular Therapy; CRS, cytokine release syndrome; CTCAE, Common Terminology Criteria for Adverse Events; ICANS, immune effector cell–associated neurotoxicity syndrome.